GliaCure is focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets.
It is known that the brain consists of two types of cells - neurons and glia. Much of the research of the last century has focused on neurons. Founder Philip Haydon’s recent work has identified a novel glia-based target that, in pre-clinical studies, is highly efficacious in reversing Alzheimer’s disease. GliaCure will initially exploit this opportunity to develop novel small molecule pharmaceuticals for the treatment of Alzheimer’s disease, a disorder that, it is estimated, will cost the US $1.1 trillion annually by 2050. GliaCure will also focus on discovering and developing related glia-targeted pharmaceuticals to treat other disorders such as traumatic brain injury, depression, Down Syndrome, Parkinson’s disease, glioblastoma, neuropathic pain, epilepsy, psychiatric and sleep disorders.